Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.51 |
| ▸ | ACHE | P22303 | 8/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 7/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5703480 | 1.00 | CCR3 (0.51) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL5407682 | 0.92 | CCR3 (0.52) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL5407692 | 0.92 | CCR3 (0.52) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL5400200 | 0.84 | CCR3 (0.42) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL6568321 | 0.84 | CCR3 (0.40) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL5402630 | 0.84 | CCR3 (0.42) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL5409708 | 0.79 | KDM4E (0.51) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL5409697 | 0.79 | KDM4E (0.51) | CCR3ACHEMAOAMAOBBCHE | |
| SCHEMBL5404630 | 0.77 | CCR3 (0.44) | CCR3HTR2A | |
| SCHEMBL6567109 | 0.77 | CCR3 (0.44) | CCR3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401814-B1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20040180926-A1 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | claimed |
| EP-1401814-B1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180926-A1 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | CCR1, CCR3, CCR4 | CCR3 2/4885ACHE 3679/4885MAOA 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.